Abstract: Methods suitable for the protection, inhibition and prevention the deleterious effects of reactive oxygen species are provided, wherein an effective amount of a tumor necrosis factor is administered. Pretreatment of tissues and organs to be transplanted is described. Perfusion solutions and the preparation of perfused, excised tissue are described.

Abstract: Immunoglobulin fusion polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.

Abstract: Methods for the treatment of allergic reactions are provided, wherein a pharmaceutically effective dose of gamma interferon is administered to a patient within a predetermined temporal period prior to or following exposure to an allergen.

Abstract: DNA isolates coding for a lymphocyte homing receptor and methods of obtaining such DNA are provided, together with expression systems for recombinant production of the lymphocyte homing receptor useful in therapeutic or diagnostic compositions.

Abstract: Tumor necrosis factors, alone or together with cytokines such as IL-1 or INF-.gamma., are capable of serving as non-toxic vaccine adjuvants.

Abstract: Antibody is provided which is capable of neutralizing the in vitro anti-neoplastic cellular activity of lymphotoxin. This antibody, which preferably is produced of monoclonal fusions, can be used in assays for lymphotoxin or for immunoaffinity purification of lymphotoxin.

Abstract: Disclosed are improved methods for the treatment of lung membrane diseases such as respiratory distress syndrome (RDS) or idiopathic RDS, employing compositions including therapeutically effective amounts of gamma interferon and/or tumor necrosis factor (TNF), each alone or in combination with corticosteroids, preferably employing recombinant human gamma interferon and/or TNF. Individuals, including adults or children, are administered amounts of these agents that are generally effective to induce the lungs of affected individuals to produce one or more surfactant components, including both phospholipid and surfactant protein substituents.

Abstract: Biologically active lymphotoxin polypeptide species, and derivatives, fragments, aggregates and pharmaceutically acceptable salts are provided. The lymphotoxins are substantially homogenous, and are formulated into pharmaceutical compositions. The lymphotoxins are purified to a specific activity of at least 10.sup.6 units/mg protein by using hydrophobic substances and/or immobilized lentil lectin, or with the use of other chromatographic processes such as ion exchange chromatography, HPLC or gel filtration.

Abstract: A device is provided for controlling the position of a damper within a flue or stack of a forced air heating or cooling system or a commercial or industrial boiler. The device comprises a damper plate and means to control rotation of the plate within a flue under force supplied by the movement within the flue of air or gases.